Mandate

Vinge has advised Tobii in connection with the listing of Tobii Dynavox

Vinge has advised Tobii and Tobii Dynavox in connection with the distribution of the shares in Tobii Dynavox to the shareholders in Tobii as well as the listing of Tobii Dynavox’s ordinary shares on Nasdaq Stockholm. The prospectus was published 23 November 2021 and the first day of trading on Nasdaq Stockholm was 9 December 2021.

Tobii Dynavox is the global leader in assistive technology for communication. The company’s custom designed solutions enable people with disabilities such as cerebral palsy, ALS and spinal cord injury to communicate with a voice of their own, develop literacy skills and live more independently. To date, hundreds of thousands of people worldwide have benefited from their integrated solutions, which include hardware, software, clinically developed language systems, special education tools, training, and dedicated support. The company offers an extensive funding support system to reach as many people as possible. Headquartered in Sweden, Tobii Dynavox employs around 500 people with offices in the US, the UK, Norway and China, and reselling partners in 60+ countries.

Vinge’s team consisted of Jesper Schönbeck, Amanda Knutsson, Joel Magnusson, Emil Lindwall, Pernilla Björklund, Henrik Wastensson, Victor Ericsson and Emelie Svanberg,Maria Dahlin Kolvik, Christina Odengran, Ellinor Wargenbrant, Eléonore Friberg, Jolene Reimerson and Viktoria Owetz Leyva.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025